Together, these data demonstrated that DYRK1A suppression enhanced the anti-NSCLC activity of Bcl-2 antagonists by reducing Mcl-1 expression, both in NSCLC cell lines and primary NSCLC cells. Here, BCL2 is linked to non-small cell lung carcinoma.